By Dr Robert W Malone
Strong data from a peer reviewed article in the journal of Clinical Infectious Disease shows that there is a significant increase in the risk of myocarditis/pericarditis following Comirnaty vaccination among Chinese male adolescents, especially after the second dose. Onset of myocarditis was a median of 2 days after vaccination. The clinically significant (acute and/or “mild”) myocarditis/pericarditis incidence rate came in at one out of every 2680 young males.
The results conclude with:
“Among male adolescents, the incidence after the first and second doses were 5.57 (95% CI 2.38-12.53) and 37.32 (95% CI 26.98-51.25) per 100,000 persons vaccinated.”
Analysis: 37.32 per 100,000 = 1 in 2680 young men developed myocarditis/pericarditis within two weeks of their second vaccination (median time to disease: 2 days). This study was an analysis of hospital records of myocarditis/pericarditis, so did not include adolescents who may have developed the disease but did not seek medical attention.
Many pediatric cardiologists including my colleague and friend Dr. Kirk Milhoan, MD, PhD (MD board certified in pediatric cardiology, PhD. in vascular inflammation) assert that there is no such thing as “mild” myocarditis in children. Myocarditis causes heart damage. Heart damage is for life – the heart does not heal by replacing damaged cells. It scars. Scars in the heart can lead to changes in electrical conduction in heart muscle, which in turn can result in “sudden death” due to changes in heart beat regularity and muscular contraction of the heart. These events may happen at any time, particularly when the heart is stressed in some way.
Results (from the abstract):
“Between 14 June 2021 and 4 September 2021, 33 Chinese adolescents who developed acute myocarditis/pericarditis following Comirnaty vaccination were identified. 29 (87.88%) were males and 4 (12.12%) were females, with a median age of 15.25 years. 27 (81.82%) and 6 (18.18%) cases developed acute myocarditis/pericarditis after receiving the second and first dose, respectively. All cases are mild and required only conservative management. The overall incidence of acute myocarditis/pericarditis was 18.52 (95% Confidence Interval [CI], 11.67-29.01) per 100,000 persons vaccinated. The incidence after the first and second doses were 3.37 (95%CI 1.12-9.51) and 21.22 (95%CI 13.78-32.28 per 100,000 persons vaccinated, respectively. Among male adolescents, the incidence after the first and second doses were 5.57 (95% CI 2.38-12.53) and 37.32 (95% CI 26.98-51.25) per 100,000 persons vaccinated.”
Conclusion from the Abstract:
“There is a significant increase in the risk of acute myocarditis/pericarditis following Comirnaty vaccination among Chinese male adolescents, especially after the second dose.”
The link for the abstract to this paper :
My interpretation? More evidence that vaccinating young people with this vaccine is bad medicine, bad policy and shows poor decision making by the FDA on the rushed decision to grant EUA status to these vaccines, particularly for male adolescents and male young adults. With strong data such as this paper, parents should consider very carefully before making the decision to vaccinate children. Finally, the idea that this vaccine should be mandated in our schools is absolutely wrong, and if we do not reverse these decisions by national authorities, states, and local school boards we will be sentencing a significant fraction of our youth to government-mandated heart damage.
Dr Robert Malone is an internationally recognized scientist/physician and the original inventor of mRNA vaccination as a technology, DNA vaccination, and multiple non-viral DNA and RNA/mRNA platform delivery technologies. He holds numerous fundamental domestic and foreign patents in the fields of gene delivery, delivery formulations, and vaccines: including for fundamental DNA and RNA/mRNA vaccine technologies.
Dr Malone has approximately 100 scientific publications with over 12,000 citations of his work (per Google Scholar with an “outstanding” impact factor rating). He has been an invited speaker at over 50 conferences, has chaired numerous conferences and has sat on or served as chairperson on HHS and DoD committees. He currently sits as a non-voting member on the NIH ACTIV committee, which is tasked with managing clinical research for a variety of drug and antibody treatments for COVID-19.
Dr Malone received his medical degree from the Northwestern Feinberg School of Medicine. He completed the Harvard Medical School fellowship as a global clinical research scholar in 2016 and was scientifically trained at the University of California at Davis, the University of California at San Diego, and at the Salk Institute Molecular Biology and Virology laboratories. He has served as an assistant and associate professor of pathology and surgery at the University of California at Davis, the University of Maryland, and the Armed Forces University of the Health Sciences.
